- Report
- October 2024
- 200 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Report
- April 2025
- 183 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- August 2022
- 120 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- August 2024
- 80 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Palonosetron is a 5-HT3 receptor antagonist used to treat nausea and vomiting caused by chemotherapy and radiotherapy. It is a member of the serotonin antagonist and reuptake inhibitor (SARI) class of drugs, and is the only 5-HT3 receptor antagonist approved for use in the United States. Palonosetron is used to prevent and treat acute and delayed nausea and vomiting associated with chemotherapy and radiotherapy. It is also used to prevent nausea and vomiting associated with surgery. Palonosetron is available in both oral and intravenous formulations.
Palonosetron is marketed by several pharmaceutical companies, including Eisai, Teva Pharmaceuticals, and Sun Pharmaceuticals. It is also available as a generic drug in some countries. Palonosetron is approved for use in more than 70 countries worldwide.
Companies in the Palonosetron market include Eisai, Teva Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, and Sandoz. Show Less Read more
